Experience

Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…

Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of approximately SEK 265 million.  Xspray was founded in 2003…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk advised Toyota Motor Credit Corporation in connection with an SEC-registered offering of $600 million aggregate principal amount of floating-rate medium-term notes, Series B due…

Davis Polk advised Arcos Dorados Holdings Inc. in connection with the exchange of approximately $131.5 million aggregate principal amount of its 6.625% senior notes due 2023 for its 5.785%…

Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered shelf takedown of $1 billion aggregate principal amount of 2.032%…

Davis Polk advised the underwriters on an SEC-registered offering by Baidu, Inc. of its $650 million 1.720% notes due 2026 and $300 million 2.375% notes due 2030.Baidu, Inc. is a leading…

Davis Polk advised the dealer managers in connection with Empresa Eléctrica Angamos SpA’s cash tender offer for up to the outstanding $388 million aggregate principal amount of its 4.875%…

Davis Polk advised the joint book-running managers in connection with a Rule 144A/Regulation S offering of $400 million aggregate principal amount of 2.807% senior notes due 2050 by…

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …